Novavax, Inc. (NVAX) said the first volunteers have been enrolled in the phase 2 portion of the ongoing clinical trial to evaluate the immunogenicity and safety of NVX-CoV2373, the company's COVID-19 vaccine candidate. The phase 2 portion of the phase 1/2 trial trial expands on the age range of the phase 1 portion by including older adults 60-84 years of age as approximately 50 percent of the trial's population.
In the phase 1 portion of the phase 1/2 clinical trial, conducted in Australia, NVX-CoV2373 was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera.
Gregory Glenn, President, Research and Development at Novavax, said: "We know that the world is closely watching all of these trials, and we anticipate interim data from this trial in the fourth quarter of this year."
For comments and feedback: editorial@rttnews.com